Zobrazeno 1 - 10
of 263
pro vyhledávání: '"Jungsil Ro"'
Autor:
Johannes Ettl, Seock-Ah Im, Jungsil Ro, Norikazu Masuda, Marco Colleoni, Patrick Schnell, Eustratios Bananis, Dongrui R. Lu, Massimo Cristofanilli, Hope S. Rugo, Richard S. Finn
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-10 (2020)
Abstract Background Palbociclib improves outcomes for women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC). Dose reductions are recommended for the management of hematolog
Externí odkaz:
https://doaj.org/article/c9f4326e37ad41e7874ee10f377c5ba6
Autor:
Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, Young-Hyuck Im, Kenichi Inoue, Yoshiaki Rai, Rikiya Nakamura, Jee Hyun Kim, Justin T. Hoffman, Ke Zhang, Carla Giorgetti, Shrividya Iyer, Patrick T. Schnell, Cynthia Huang Bartlett, Jungsil Ro
Publikováno v:
Journal of Global Oncology, Vol 3, Iss 4, Pp 289-303 (2017)
Purpose: To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy–resistant metastatic breast cancer. Patients and Methods: The Palbociclib Ongoing Trials in the Management of Breast Cancer 3 (PALOMA-3) trial,
Externí odkaz:
https://doaj.org/article/1f649be8218b4119bec32926794f26b2
Autor:
Sung Hoon Sim, Chang-Dae Bae, Youngmi Kwon, Hai-Li Hwang, Shiv Poojan, Hye-In Hong, Kyungtae Kim, Seo-Hee Kang, Han-Seong Kim, Tae-Hyun Um, In Hae Park, Keun Seok Lee, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Mi-Kyung Kim, Kyeong-Man Hong, Jungsil Ro
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0182107 (2017)
Recently, we reported cytoskeleton-associated protein2 (CKAP2) as a possible new prognostic breast cancer marker. However, it has not yet been applied in clinic. Therefore, clinical significance of CKAP2 was evaluated in comparison with that of Ki-67
Externí odkaz:
https://doaj.org/article/4e6c5718b3ea4af38b8abbd539e35163
Autor:
Seohyun Lee, Arlene Lansangan Quiambao, Jeonghee Lee, Jungsil Ro, Eun-Sook Lee, So-Youn Jung, Mi-Kyung Sung, Jeongseon Kim
Publikováno v:
Nutrients, Vol 11, Iss 8, p 1949 (2019)
Breast cancer is the most common cancer in women globally, and the risk of developing breast cancer is associated with inflammation. The present study aimed to examine the association between the Dietary Inflammatory Index (DII®) and breast cancer i
Externí odkaz:
https://doaj.org/article/dba15dc280d9421a873cd35e80012cf0
Autor:
Han-Sung Kang, Sei Hyun Ahn, Siddhartha Kumar Mishra, Kyeong-Man Hong, Eun Sook Lee, Kyung Hwan Shin, Jungsil Ro, Keun Seok Lee, Mi Kyung Kim
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e84532 (2014)
The insulin-like growth factor (IGF) signaling pathway plays an important role in cancer biology. The IGF 1 receptor (IGF1R) overexpression has been associated with a number of hematological neoplasias and solid tumors including breast cancer. Howeve
Externí odkaz:
https://doaj.org/article/d2311cbce4f64bc99b2b8e8dd1281cae
Autor:
Han-Seong Kim, Jae-Soo Koh, Yong-Bock Choi, Jungsil Ro, Hyun-Kyoung Kim, Mi-Kyung Kim, Byung-Ho Nam, Kyung-Tae Kim, Vishal Chandra, Hye-Sil Seol, Woo-Chul Noh, Eun-Kyu Kim, Joobae Park, Chang-Dae Bae, Kyeong-Man Hong
Publikováno v:
PLoS ONE, Vol 9, Iss 6, p e98160 (2014)
BACKGROUND: The level of proliferation activity is a strong prognostic or predictive indicator in breast cancer, but its optimal measurement is still in debate, necessitating new proliferation markers. In the present study, the prognostic significanc
Externí odkaz:
https://doaj.org/article/ffcfe40a5d494da9aca625e9dbaff19c
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e39880 (2012)
BackgroundProgranulin (PGRN) is considered to play an important role in breast cancer tumorigenesis and in inhibiting tamoxifen-induced apoptosis. We aimed to determine whether PGRN levels are associated with breast cancer recurrence after curative s
Externí odkaz:
https://doaj.org/article/824e5f1a718d4d0ebddfc12001a0248b
Autor:
Sae-Won Han, Yongjun Cha, Agnes Paquet, Weidong Huang, Jodi Weidler, Yolanda Lie, Thomas Sherwood, Michael Bates, Mojgan Haddad, In Hae Park, Do-Youn Oh, Keun Seok Lee, Seock-Ah Im, Yung-Jue Bang, Jungsil Ro, Tae-You Kim
Publikováno v:
PLoS ONE, Vol 7, Iss 7, p e39943 (2012)
BACKGROUND: Lapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer. We have investigated the correlation between quantitative measures of HER2, p95HER2, and HER3 and treatment ou
Externí odkaz:
https://doaj.org/article/526defc171974c2982015ad0bc9d86dd
Autor:
Mark D. Pegram, Sanne L. de Haas, Steve Olsen, Meghna K. Samant, Alice E. Guardino, Jens Huober, Jungsil Ro, Sunil Verma, Gail D. Lewis Phillips, José Baselga
Purpose: HER2-positive breast cancer is heterogeneous. Some tumors express mutations, like activating PIK3CA mutations or reduced PTEN expression, that negatively correlate with response to HER2-targeted therapies. In this exploratory analysis, we in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60a7b946dd1897f953de04735e267dbc
https://doi.org/10.1158/1078-0432.c.6523352.v1
https://doi.org/10.1158/1078-0432.c.6523352.v1
Autor:
Mark D. Pegram, Sanne L. de Haas, Steve Olsen, Meghna K. Samant, Alice E. Guardino, Jens Huober, Jungsil Ro, Sunil Verma, Gail D. Lewis Phillips, José Baselga
Supplementary Fig 1. Overall survival by HER2 mRNA percentile Supplementary Fig 2. Patient disposition and biomarker availability in the EMILIA trial. Supplementary Fig 3. Potential mechanism by which T-DM1 may bypass a common resistance pathway in H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90a392182694566c21ada6ef2478bd88
https://doi.org/10.1158/1078-0432.22456571.v1
https://doi.org/10.1158/1078-0432.22456571.v1